Checkpoint Inhibitor Combination Well-tolerated, Effective in Ovarian Cancer Patients, Phase 1b Trial Shows

Checkpoint Inhibitor Combination Well-tolerated, Effective in Ovarian Cancer Patients, Phase 1b Trial Shows
A combination of two checkpoint inhibitor therapies, magrolimab (Hu5F9-G4) and Bavencio (avelumab), has an acceptable safety profile, is well-tolerated, and stabilizes disease in more than half of heavily-treated ovarian cancer patients, results from a Phase 1b trial show. The findings of the trial (NCT03558139) were presented in a poster at the 2020 Clinical Immuno-Oncology Symposium, organized by the American Society of Clinical Oncology
Subscribe or to access all post and page content.